P1185 INTERIM SVR12 RESULTS FROM THE TELAPREVIR PHASE 3B REPLACE STUDY IN TREATMENT-NAIVE STABLE LIVER TRANSPLANT PATIENTS WITH GENOTYPE 1 HCV INFECTION

P1185 INTERIM SVR12 RESULTS FROM THE TELAPREVIR PHASE 3B REPLACE STUDY IN TREATMENT-NAIVE STABLE LIVER TRANSPLANT PATIENTS WITH GENOTYPE 1 HCV INFECTION X. Forns, D. Samuel, D. Mutimer, S. Fagiouli, M. Navasa, K. Agarwal, M. Berenguer, M. Colombo, K. Herzer, F. Nevens, R. Van Solingen-Ristea, D. Luo, I. Dierynck, J. Witek. Liver Unit, Hospital Clinic, CIBEREHD and IDIBAPS, Barcelona, Spain; Centre Hepatobiliaire, Hospital Paul Brousse, University Paris South Villejuif, Paris, France; Queen Elizabeth Hospital and NIHR BRU, Birmingham, United Kingdom; Gastroenterology and Transplant Hepatology, Papa Giovanni XXIII Hospital, Bergamo, Italy; Liver Unit, Hospital Clinic Barcelona, Barcelona, Spain; Kings College Hospital, London, United Kingdom; La Fe Hospital and CIBEREHD, Valencia, Spain; Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Universita degli Studi di Milano, Milan, Italy; Liver Transplantation Unit, University Hospital Essen, Essen, Germany; University Hospitals KU Leuven, Leuven, Belgium; Janssen Research & Development, LLC, Titusville, NJ, United States; Janssen Infectious Diseases BVBA, Beerse, Belgium E-mail: xforns@clinic.ub.es